Show simple item record

dc.contributor.authorGhaffar, Khairunnisa A
dc.contributor.authorMarasini, Nirmal
dc.contributor.authorGiddam, Ashwini K
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorGood, Michael F
dc.contributor.authorSkwarczynski, Mariusz
dc.contributor.authorToth, Istvan
dc.date.accessioned2017-09-01T02:18:14Z
dc.date.available2017-09-01T02:18:14Z
dc.date.issued2017
dc.identifier.issn1573-4064
dc.identifier.doi10.2174/1573406412666160720093138
dc.identifier.urihttp://hdl.handle.net/10072/345694
dc.description.abstractBackground: Group A streptococcus (GAS) is an exclusively human pathogenic bacteria. A delay in treatment of GAS infection often lead to severe diseases such as rheumatic heart disease which attributes to hundreds of thousands deaths annually. For the past few decades, the quest for a commercial GAS vaccine has been futile. Currently one of the most investigated strategies to develop vaccine against GAS includes the use of conserved epitopes from major virulent factor of GAS, M-protein. Methods: In this study, cationic liposomes of various sizes (70 nm to 1000 nm) were prepared with dimethyldioctadecylammonium bromide (DDAB) encapsulating lipopeptide bearing M-protein derived B-cell epitope (J14). Results: Smaller liposomes induced higher antibody titres, though the differences between groups were not statistically significant. Conclusion: Nonetheless, all mice which were immunized with liposome-lipopeptide delivery system elicited high levels of systemic (IgG) and mucosal antibodies (IgA), which were discernably higher than those induced with the help of commercial adjuvant (cholera toxin B subunit).
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherBentham Science Publishers Ltd.
dc.relation.ispartofpagefrom22
dc.relation.ispartofpageto27
dc.relation.ispartofissue1
dc.relation.ispartofjournalMedicinal Chemistry
dc.relation.ispartofvolume13
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry not elsewhere classified
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode030499
dc.subject.fieldofresearchcode0304
dc.subject.fieldofresearchcode1115
dc.titleThe role of size in development of mucosal liposome-lipopeptide vaccine candidates against group A streptococcus
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorBatzloff, Michael R.
gro.griffith.authorGood, Michael F.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record